Background/Aims: The Hp1/Hp2 DNA polymorphism has previously been implicated in susceptibility to diabetic nephropathy in some but not all studies. In an attempt to clarify these conflicting findings, we conducted a case-control association study in a Caucasian population. Methods: We recruited 224 and 285 type 1 diabetic patients with (cases) and without (controls) nephropathy, respectively, from 2 centres based in Northern Ireland and the Republic of Ireland. Hp1/Hp2 genotyping was performed using a combination of long-range and multiplex PCR. Allele and genotype frequencies in cases and controls were compared using the χ2 test. Results: There was a statistically significant increase in the frequency of the Hp2 allele in cases compared to controls (65.6 vs. 58.6%, OR = 1.35, 95% CI: 1.04–1.76, p = 0.03). The distributions of genotypes were in Hardy-Weinberg equilibrium for both cases and controls, and the overall frequency of the Hp1 allele was 38.3%, which is similar to that found in other Western European populations. Conclusions: The results suggest that the Hp2 allele may confer susceptibility to nephropathy in patients with type 1 diabetes.

1.
U.S. Renal Data System, USRDS 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005.
2.
Seaquist ER, Goetz FC, Rich S, Barbosa J: Familial clustering of diabetic kidney disease: evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989;320:1161–1165.
[PubMed]
3.
Quinn M, Angelico MC, Warram JH, Krolewski AS: Familial factors determine the development of nephropathy in patients with IDDM. Diabetologia 1996;39:940–945.
[PubMed]
4.
Lee HB, Yu MR, Yang Y, Jaing Z, Ha H: Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003;14:S241–S245.
5.
Langlois MR, Delanghe JR: Biological and clinical significance of haptoglobin polymorphisms in humans. Clin Chem 1996;42:1589–1600.
[PubMed]
6.
Levy AP, Roguin A, Hochberg I, et al: Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med 2000;343:969–970.
[PubMed]
7.
Nakhoul FM, Zoabi R, Kanter Y, et al: Haptoglobin phenotype and diabetic nephropathy. Diabetologia 2001;44:602–604.
[PubMed]
8.
Moczulski DK, Rogus JJ, Krolewski AS: Haptoglobin phenotype and diabetes. Diabetologia 2001;44:2237–2239.
[PubMed]
9.
Koda Y, Soejima M, Yamagishi S, et al: Haptoglobin genotype and diabetic microangiopathies in Japanese diabetic patients. Diabetologia 2002;45:1039–1040.
[PubMed]
10.
Conway BR, Maxwell AP, Savage DA, et al: Association between variation in the actin-binding gene caldesmon and diabetic nephropathy in type 1 diabetes. Diabetes 2004;53:1162–1165.
[PubMed]
You do not currently have access to this content.